Myomo, Inc. (MYO): Price and Financial Metrics


Myomo, Inc. (MYO): $11.72

-0.97 (-7.64%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MYO POWR Grades


  • Growth is the dimension where MYO ranks best; there it ranks ahead of 78.56% of US stocks.
  • The strongest trend for MYO is in Stability, which has been heading up over the past 48 weeks.
  • MYO ranks lowest in Quality; there it ranks in the 5th percentile.

MYO Stock Summary

  • Myomo Inc's market capitalization of $71,220,134 is ahead of merely 9.83% of US-listed equities.
  • For MYO, its debt to operating expenses ratio is greater than that reported by just 9.33% of US equities we're observing.
  • As for revenue growth, note that MYO's revenue has grown 179.35% over the past 12 months; that beats the revenue growth of 96.04% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Myomo Inc are HAPP, AGRX, MYGN, OFLX, and NEOG.
  • MYO's SEC filings can be seen here. And to visit Myomo Inc's official web site, go to www.myomo.com.

MYO Valuation Summary

  • In comparison to the median Healthcare stock, MYO's price/earnings ratio is 116.71% lower, now standing at -6.1.
  • Over the past 51 months, MYO's EV/EBIT ratio has gone up 0.8.
  • Over the past 51 months, MYO's price/sales ratio has gone down 51.6.

Below are key valuation metrics over time for MYO.

Stock Date P/S P/B P/E EV/EBIT
MYO 2021-08-31 5.5 4.5 -6.1 -4.9
MYO 2021-08-30 5.4 4.4 -6.0 -4.7
MYO 2021-08-27 5.4 4.4 -6.0 -4.7
MYO 2021-08-26 5.4 4.4 -6.0 -4.8
MYO 2021-08-25 5.3 4.3 -5.9 -4.7
MYO 2021-08-24 5.3 4.3 -5.8 -4.6

MYO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MYO has a Quality Grade of D, ranking ahead of 5.8% of graded US stocks.
  • MYO's asset turnover comes in at 0.65 -- ranking 59th of 183 Medical Equipment stocks.
  • BDX, DXCM, and ATRI are the stocks whose asset turnover ratios are most correlated with MYO.

The table below shows MYO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.650 0.696 -26.424
2021-03-31 0.559 0.674 -133.294
2020-12-31 0.516 0.657 78.522
2020-09-30 0.419 0.644 -102.361
2020-06-30 0.386 0.692 -74.662
2020-03-31 0.433 0.736 -76.097

MYO Stock Price Chart Interactive Chart >

Price chart for MYO

MYO Price/Volume Stats

Current price $11.72 52-week high $18.88
Prev. close $12.69 52-week low $4.30
Day low $11.54 Volume 75,900
Day high $12.69 Avg. volume 121,797
50-day MA $9.96 Dividend yield N/A
200-day MA $10.51 Market Cap 67.16M

Myomo, Inc. (MYO) Company Bio


Myomo, Inc. operates as a medical robotics company. The Company offers expanded mobility for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets arm braces to restore function in the paralyzed and weakened arms and hands of individuals that have suffered a stroke, spinal cord, and nerve injury.


MYO Latest News Stream


Event/Time News Detail
Loading, please wait...

MYO Latest Social Stream


Loading social stream, please wait...

View Full MYO Social Stream

Latest MYO News From Around the Web

Below are the latest news stories about Myomo Inc that investors may wish to consider to help them evaluate MYO as an investment opportunity.

Myomo, Inc. Announces Granting of Patents in China and Hong Kong

BOSTON, September 07, 2021--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the granting of patents in China and Hong Kong covering the Company’s most advanced products. Patent number ZL201680032072 was issued in China and patent number 1251447B was issued in Hong Kong. The patents are titled "Powered Orthotic Device and Me

Yahoo | September 7, 2021

Myomos Wearable Completes First Phase of Brain-Computer Interface Trial

Concept: Massachusetts medical robotics provider Myomo has developed MyoPro wearable to offer enhanced functionality to patients with neurological disorders and upper-limb paralysis. It has recently announced that Thomas Jefferson University has conducted the first phase of clinical trials leveraging sensors embedded in the brain to control a MyoPro-boosted brace worn by a stroke patient. Nature [] The post Myomos Wearable Completes First Phase of Brain-Computer Interface Trial appeared first on Verdict .

Verdict | September 6, 2021

Myomo, Inc. Announces Participation in Three September Investment Conferences

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American:MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomos chairman and chief executive officer, and David Henry, Myomos chief financial officer, will participate in three investment conferences in September. They are: 2021 Colliers Institutional Investor Conference, which will be h

Business Wire | September 2, 2021

Myomo EPS beats by $0.14, beats on revenue

No summary available.

Seeking Alpha | August 9, 2021

Myomo'' (MYO) CEO Paul Gudonis on Q2 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | August 9, 2021

Read More 'MYO' Stories Here

MYO Price Returns

1-mo 11.62%
3-mo 8.52%
6-mo -11.35%
1-year 159.29%
3-year -79.86%
5-year N/A
YTD 74.15%
2020 -25.42%
2019 -79.11%
2018 -61.60%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8569 seconds.